5.25
3.55%
0.18
アフターアワーズ:
5.25
前日終値:
$5.07
開ける:
$5.07
24時間の取引高:
240.53K
Relative Volume:
5.38
時価総額:
$427.92M
収益:
$163.13M
当期純損益:
$-34.75M
株価収益率:
-10.19
EPS:
-0.5152
ネットキャッシュフロー:
$-231.66M
1週間 パフォーマンス:
+10.76%
1か月 パフォーマンス:
+21.53%
6か月 パフォーマンス:
-27.08%
1年 パフォーマンス:
-35.58%
Valneva Se Adr Stock (VALN) Company Profile
VALN を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
5.25 | 427.92M | 163.13M | -34.75M | -231.66M | -0.5152 |
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2022-08-03 | 開始されました | H.C. Wainwright | Buy |
Valneva Se Adr (VALN) 最新ニュース
Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock - Yahoo Finance
Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine - GlobeNewswire Inc.
VALNEVA - GlobeNewswire Inc.
Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock - Yahoo Finance
Valneva SE earnings missed by $0.02, revenue fell short of estimates - Investing.com
Valneva SE (VALN) Q3 2024 Earnings Report Preview: What to Look For - Yahoo Finance
H.C. Wainwright maintains Buy rating on Valneva SE stock, lowers price target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Valneva SE stock, lowers price target - Investing.com
Valneva SE Declaration of shares and voting rights - GlobeNewswire Inc.
H.C. Wainwright updates Valneva SE outlook following capital raise, reiterates Buy - Investing.com
H.C. Wainwright updates Valneva SE outlook following capital raise, reiterates Buy By Investing.com - Investing.com South Africa
In-Depth Examination Of 6 Analyst Recommendations For Valneva - Benzinga
Valneva shares hold strong with buy rating on Lyme vaccine data - Investing.com
Wall Street Analysts Predict a 150.41% Upside in Valneva (VALN): Here's What You Should Know - MSN
Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock - Zacks Investment Research
How Much Upside is Left in Valneva (VALN)? Wall Street Analysts Think 135.3% - Yahoo Finance
Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect? - Zacks Investment Research
Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine - Zacks Investment Research
Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval - Yahoo Finance
Earnings call: Valneva reports robust growth and strategic R&D focus By Investing.com - Investing.com South Africa
Valneva (VALN) Stock Down 53% in the Past Year: Here's Why - Nasdaq
Valneva (VALN) Stock Down 61.5% in the Past Year: Here's Why - Yahoo Finance
Valneva (VALN) Down on its COVID-19 Vaccine Update in Europe - Zacks Investment Research
Valneva (VALN) Down as EU Considers Ending COVID-Vaccine Deal - Yahoo Finance
5 Top Health Care Stocks To Watch In The Stock Market Today - Stock Market
Valneva Stock Is Jumping on European Vaccine Supply Deal - Barron's
Valneva Stock Surges After EU Vaccine Deal - Investing.com
Valneva Shares Off 12% On Share Offering News By Investing.com - Investing.com UK
Valneva (VALN) Reports Positive Data From COVID Vaccine Study - Nasdaq
Valneva Stock Plunges as U.K. Drops Covid-19 Vaccine Deal - Barron's
EU set to sign off new Pfizer vaccine contract as soon as Friday - Luxembourg Times
Shareholder Structure - Valneva
Stock Price - Valneva
Valneva Se Adr (VALN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):